With a remit across healthcare, life sciences and advanced materials, Merck’s corporate venturing unit is scoping an opportunity-filled landscape.

M Ventures, the Netherlands-based corporate venturing subsidiary of Germany-headquartered pharmaceutical firm Merck Group, has had a busy start to the year, as its wide technological remit allows it opportunities other pharmaceutical companies might not have.

The unit invested in Future Fertility, a provider of diagnostic software for in vitro fertilisation, in January and followed that by participating in a $56m series A round for Celestial AI, the developer of a hardware and software platform for use in machine…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn